Benmelstobart

DB17473InvestigationalProtein Based Therapies

APL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1 (PD-L1).

Mechanism: Pharmacologically active on Programmed cell death 1 ligand 1
Curator reviewed
Also known as: gamma1 heavy chain humanized (1-446) [VH (Homo sapiens IGHV2-5*01 (78.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.7.10] (26-33.51-57.96-105)) (1-116)-Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, G1v66 CH2 A27 (CH1 K120(213) (117-214), hinge 1-15 · Immunoglobulin G1 [264-alanine], anti-(human programmed death-ligand 1) (human-Mus musculus monoclonal CBT-502 γ1-chain), disulfide with human-Mus musculus monoclonal CBT-502 κ-chain, dimer
Code names: APL-502 · CBT-502 · TQ-B2450

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

90Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Benmelstobart, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.